\(\bf Introduction:\) Studies on pancreatic neuroendocrine tumors (PanNETs) regarding loss of \(\it ATRX\), \(\it DAXX\), or frequency of microsatellite instability (MSI) show inconclusive results. So far, data on corresponding metastaseshave not been published. \(\bf Methods:\) We performed immunohistochemistry (IHC) of \(\it ATRX\), \(\it DAXX\), (\it MSH2\), (\it MSH6\), (\it MLH1\), and (\it PMS2\) on 74 PanNETs and 19 metastases. \(\it ATRX\)- and \(\it DAXX\)-negative PanNETs were further sequenced for mutations. We used polymerase chain reaction for MSI on cases with IHC loss of (\it MSH2\), (\it MSH6\), (\it MLH1\), and (\it PMS2\). \(\bf Results:\) Immunohistochemical loss of \(\it DAXX\) and \(\it ATRX\) was observed in 8/74 (11...
Background: Pancreatic neuroendocrine tumors (PNET) have an unpredictable biological behavior that c...
Current knowledge on the molecular landscape of pancreatic neuroendocrine tumors (PanNETs) has advan...
The prospect that pancreatic cancer will be the second most common cause of cancer death by 2030 is ...
\(\bf Introduction:\) Studies on pancreatic neuroendocrine tumors (PanNETs) regarding loss of \(\it ...
\(\bf Introduction:\) Studies on pancreatic neuroendocrine tumors (PanNETs) regarding loss of \(\it ...
Item does not contain fulltextPancreatic neuroendocrine tumors (PanNETs) are rare neoplasms accounti...
Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms accounting for 1% to 2% of all pancrea...
BACKGROUND & AIMS Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and genetically hete...
Objective:The aim of this study was to investigate the key molecular alterations in small primary pa...
Objective:The aim of this study was to investigate the key molecular alterations in small primary pa...
Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and genetically heterogeneous. Chromosome...
Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and genetically heterogeneous. Chromosome...
Management of localized well-differentiated pancreatic neuroendocrine tumors (panNETs) is controvers...
Objective:The aim of this study was to investigate the key molecular alterations in small primary pa...
Objective:The aim of this study was to investigate the key molecular alterations in small primary pa...
Background: Pancreatic neuroendocrine tumors (PNET) have an unpredictable biological behavior that c...
Current knowledge on the molecular landscape of pancreatic neuroendocrine tumors (PanNETs) has advan...
The prospect that pancreatic cancer will be the second most common cause of cancer death by 2030 is ...
\(\bf Introduction:\) Studies on pancreatic neuroendocrine tumors (PanNETs) regarding loss of \(\it ...
\(\bf Introduction:\) Studies on pancreatic neuroendocrine tumors (PanNETs) regarding loss of \(\it ...
Item does not contain fulltextPancreatic neuroendocrine tumors (PanNETs) are rare neoplasms accounti...
Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms accounting for 1% to 2% of all pancrea...
BACKGROUND & AIMS Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and genetically hete...
Objective:The aim of this study was to investigate the key molecular alterations in small primary pa...
Objective:The aim of this study was to investigate the key molecular alterations in small primary pa...
Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and genetically heterogeneous. Chromosome...
Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and genetically heterogeneous. Chromosome...
Management of localized well-differentiated pancreatic neuroendocrine tumors (panNETs) is controvers...
Objective:The aim of this study was to investigate the key molecular alterations in small primary pa...
Objective:The aim of this study was to investigate the key molecular alterations in small primary pa...
Background: Pancreatic neuroendocrine tumors (PNET) have an unpredictable biological behavior that c...
Current knowledge on the molecular landscape of pancreatic neuroendocrine tumors (PanNETs) has advan...
The prospect that pancreatic cancer will be the second most common cause of cancer death by 2030 is ...